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ABSTRACT
The emergence of targeted cancer therapy has been limited by the paucity of 
determinants which are tumor-specific and generally associated with disease, and 
have cell dynamics which effectively deploy cytotoxic payloads. Guanylyl cyclase C 
(GUCY2C) may be ideal for targeting because it is normally expressed only in insulated 
barrier compartments, including intestine and brain, but over-expressed by systemic 
metastatic colorectal tumors. Here, we reveal that GUCY2C rapidly internalizes from 
the cell surface to lysosomes in intestinal and colorectal cancer cells. Endocytosis is 
independent of ligand binding and receptor activation, and is mediated by clathrin. 
This mechanism suggests a design for immunotoxins comprising a GUCY2C-directed 
monoclonal antibody conjugated through a reducible disulfide linkage to ricin A chain, 
which is activated to a potent cytotoxin in lysosomes. Indeed, this immunotoxin 
specifically killed GUCY2C-expressing colorectal cancer cells in a lysosomal- and 
clathrin-dependent fashion. Moreover, this immunotoxin reduced pulmonary tumors 
>80% (p<0.001), and improved survival 25% (p<0.001), in mice with established 
colorectal cancer metastases. Further, therapeutic efficacy was achieved without 
histologic evidence of toxicity in normal tissues. These observations support GUCY2C-
targeted immunotoxins as novel therapeutics for metastatic tumors originating in the 
GI tract, including colorectum, stomach, esophagus, and pancreas.
INTRODUCTION
Immunotoxins (ITs) have emerged as a key 
weapon in the arsenal against metastatic cancer [1, 2]. 
Originally described by Ehrlich, ITs are the embodiment 
of his concept of the magic bullet, combining the specific 
targeting of antibodies with the exquisite potency of 
cytotoxins to kill cells [3, 4]. Early studies combining 
holotoxins and antibodies against proteins with increased 
expression in cancer failed because of the absence of 
tumor specificity, producing normal tissue destruction 
[1, 2]. Improvements in natural toxin payloads have 
removed their promiscuous binding domains, emulated 
their linkages to these binding domains, and modified 
antigenic determinants to evade immune clearance [5]. In 
addition, novel cytotoxic payloads are emerging, including 
semiconductor quantum dots for photodynamic therapy 
and nanoshells which encapsulate traditional drugs 
but cloak them from normal tissue [6]. However, while 
cytotoxic payloads and linker technologies have evolved, 
one limitation to clinical implementation of immunotoxins 
is the availability of tumor-specific targets with cellular 
dynamics that effectively deploy cytotoxic payloads.
Guanylyl cyclase C (GUCY2C), the cell surface 
receptor for diarrheagenic bacterial heat-stable 
enterotoxins and the endogenous paracrine hormones 
guanylin and uroguanylin [7], is primarily expressed in 
apical membranes [8] of intestinal epithelial cells [9-
12], segregated from the systemic compartment by the 
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intestinal barrier [13-18]. Similarly, it is expressed by 
select neurons in hypothalamus, mediating a novel gut 
brain endocrine axis regulating appetite [19], and separated 
from the systemic compartment by the blood-brain barrier 
[20]. Importantly, GUCY2C is over-expressed by primary 
and metastatic colorectal tumors [9-11, 21, 22]. In that 
context, GUCY2C has emerged as a novel vaccine target 
to treat and prevent colorectal cancer metastases without 
normal tissue damage [23-26]. These characteristics 
suggest that GCC may qualify as an effective therapeutic 
target for immunotoxins in metastatic colorectal cancer, 
the second leading cause of cancer mortality in the United 
States and the fourth most common cause of cancer 
worldwide [27]. Here, we define the cellular dynamics of 
GUCY2C, and leverage those characteristics to develop 
immunotoxins with therapeutic utility in mouse models of 
metastatic colorectal cancer.
RESULTS
mAbs Recognize the Extracellular Domain, 
Without Disrupting Receptor Function, in 
GUCY2C
We created three unique mouse mAbs (MS7, MS20, 
MS24) [19] that specifically recognize the extracellular 
domain of GUCY2C (Supplemental Fig. 1A). MS20 
recognized both mouse and human GUCY2C, and was 
utilized in the present studies. These mAbs did not directly 
activate GUCY2C and did not block its activation by ST 
(Supplemental Fig. 1B), demonstrating their inactivity 
as pharmacophores at the receptor binding site and their 
utility as inert probes of GUCY2C cellular dynamics.
Lysosomotropic Endocytosis of GUCY2C
CT26 mouse colorectal cancer cells [28], which 
are devoid of endogenous GUCY2C expression, were 
engineered to express mouse GUCY2C (CT26.GUCY2C) 
[23-25]. Unexpectedly, whole cell IF staining with 
MS20 revealed that GUCY2C primarily resided in the 
Figure 1: Intracellular localization of GUCY2C in intestinal epithelial and colorectal cancer cells. Immunofluorescent 
staining with GUCY2CmAb (green), with DAPI counterstain for nuclei (blue), in (A) CT26 and CT26.GUCY2C murine colorectal cancer 
cells or (B) colon from GUCY2C KO (GUCY2C-/-) or WT (GUCY2C+/+) mice. Results are representative of at least three independent 
replicates.
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intracellular compartment (Fig. 1A) rather than on the 
cell surface as suggested by the prevailing paradigm 
[14, 29-32]. Similarly, GUCY2C in mouse intestine 
exhibited the same predominant subcellular distribution 
in wild type (GUCY2C+/+), but not in GUCY2C-deficient 
(GUCY2C-/-), mice (Fig. 1B). Co-staining with MS20 and 
Lamp1 demonstrated localization of GUCY2C within 
lysosomes of colonocytes in wild-type (GUCY2C+/+), 
but not GUCY2C-deficient (GUCY2C-/-), mice (Fig. 
2A, Supplemental Video 1). Also, whole cell IF revealed 
GUCY2C localization within lysosomes in CT26.
GUCY2C cells (Fig. 2B, left). Live cell staining at 4°C, 
which prevents endocytosis [33], demonstrated that 
MS20 was limited only to the cell surface of GUCY2C 
in CT26.GUCY2C cells (Fig. 2B, middle). However, 
warming to 37°C released MS20-GUCY2C complexes 
to internalize from the cell surface to lysosomes in the 
absence of canonical ligands (Fig. 2B, right; Supplemental 
Video 2). Indeed, MS20-GUCY2C complexes exhibited 
rapid ligand-independent internalization (Supplemental 
Fig. 2). Additionally, endogenously expressed GUCY2C 
internalized to lysosomes in STC1 murine intestinal 
cancer cells (Supplemental Fig. 3). These observations 
demonstrate that GUCY2C undergoes rapid ligand-
independent internalization from the cell surface into 
the lysosomal compartment in intestinal epithelial and 
colorectal cancer cells.
Lysosomotropic Endocytosis Requires Clathrin, 
But Not Caveolin or the GUCY2C Cytoplasmic 
Domain
Receptor-dependent endocytosis is mediated by 
clathrin [34], and reducing expression of this scaffolding 
protein using three different targeted shRNA constructs 
proportionately reduced internalization of GUCY2C into 
lysosomes (Fig. 3A-C). Indeed, these analyses revealed 
Figure 2: Lysosomotropic endocytosis of GUCY2C. (A) GUCY2C immunofluorescence (green) co-localized (yellow) with 
lysosomes (red) in colons from GUCY2C+/+, but not GUCY2C-/-, mice (60x magnification). (B) CT26.GUCY2C cells imaged after 
methanol fixation (left), after 3 h exposure to GUCY2CmAb at 4°C in DMEM, washed with PBS and methanol-fixed (center), or after 
3 h exposure to GUCY2CmAb at 4°C in DMEM, washed with PBS, warmed in DMEM at 37°C for 1 h and then methanol-fixed (right). 
Following methanol fixation and permeabilization, cells were imaged for GUCY2CmAb (green), lysosomes with antibodies to Lamp1 
(red), and nuclei with DAPI (blue). Results are representative of at least three independent replicates.
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that at least 65% of the complement of GUCY2C 
resided within the intracellular compartment (Fig. 3C). 
In contrast, reducing the expression of caveolin, which 
mediates clathrin-independent endocytosis [35], in CT26.
GUCY2C cells did not alter GUCY2C lysosomotropic 
endocytosis (Supplemental Fig.4). Moreover, a truncation 
mutant of GUCY2C which lacks all intracellular 
regions and catalytic activity, but retains extracellular 
and transmembrane domains and the ability to bind 
GUCY2C ligands (GUCY2Ctm) [25], also internalized 
by a clathrin-dependent, caveolin-independent mechanism 
(Supplemental Fig. 5).
Targeting GUCY2C Lysosomotropic Endocytosis 
with Immunotoxins
Internalization of GUCY2C-mAb complexes to 
lysosomes suggests that GUCY2C may be a particularly 
tractable target for delivery of ITs. We designed an IT 
in which the sterically-hindered cleavable disulfide 
linker 4-succinimidyloxycarbonyl-α-methyl-α-[2-
pyridyldithio]-toluene (SMPT) [1, 2, 36] joined MS20 
to dgRTA by the free sulfhydryl group created after 
reduction and removal of the ricin B chain (Fig. 4A) 
[37], resulting in an immunotoxin (ITsmpt) containing 1 
dgRTA per IgG which can be liberated in lysosomes. As 
a negative control, dgRTA was conjugated to MS20 with 
m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 
producing an immunotoxin with a non-cleavable thioether 
bond (ITmbs) which cannot be liberated in lysosomes. 
Immunoblot analysis, probing for dgRTA under non-
reducing conditions, revealed a 180 kDa conjugate 
consisting of the 30 kDa dgRTA and 150 kDa MS20 IgG 
(Fig. 4B). Slight reduction of immunoglobulin heavy and 
light chains during electrophoresis produced an 80 kDa 
species representing dgRTA conjugated to the heavy chain 
of IgG (Fig. 4B). Reduction released dgRTA from ITsmpt 
and isotype control IgG immunotoxin (negative control for 
the cleavable IT; ISOsmpt), but not ITmbs, producing 30 
kDa (free dgRTA) and 80 kDa (dgRTA + IgG heavy chain) 
bands, respectively (Fig. 4B).
MS20 conjugated by cleavable or non-cleavable 
linkers recognized GUCY2C (Fig. 4C) and delivered 
antigen-targeted dgRTA (Fig. 4D). In that context, ITsmpt 
(Fig. 5A), but not ISOsmpt (Fig. 5B), specifically killed 
Figure 3: Lysosomotropic endocytosis of GUCY2C is clathrin-dependent. (A) Representative single cell images showing 
internalized GUCY2C (green) detected as in A-C in cells with stably transfected control (I) or clathrin-specific (II) shRNA. Cells were 
counterstained with antibodies to clathrin (red) and DAPI for nuclei (blue). The intracellular compartment was selected for quantification 
(dotted white line). (B) Quantification of clathrin knockdown and (C) GUCY2C internalization in cells treated with control (shCTRL) or 
three different clathrin-specific shRNAs (shCLTC-1, 2 and 3). Analyses were performed in a blinded fashion and data are mean ± SEM of 
at least ten cells. *** p<0.0001, one-way ANOVA.
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CT26.GUCY2C, but not CT26, cells (Fig. 5C) in a 
dose-dependent fashion. The non-cleavable ITmbs was 
minimally effective compared to ITsmpt (extrapolated 
Kd ITmbs, 1.158 µg/mL vs Kd ITsmpt, 0.019 µg/mL; 
p<0.0001; Fig. 5D), supporting liberation of dgRTA 
from the IT in lysosomes. Further, shRNA targeting 
clathrin eliminated the cytotoxicity of ITsmpt (Fig. 5E-F, 
Supplemental Fig. 6). Moreover, ITsmpt, but not ISOsmpt, 
specifically killed GUCY2Ctm in a clathrin-dependent 
fashion (Supplemental Fig. 6). As in CT26.GUCY2C 
cells, the non-cleavable ITmbs was only weakly active, 
compared to the cleavable ITsmpt, in CT26.GUCY2Ctm 
cells (extrapolated Kd ITmbs, 0.483 µg/ml vs Kd ITsmpt, 
0.016 µg/mL; p<0.0001; Supplemental Fig. 6). Thus, 
MS20 IT targets antibody-drug conjugate to cell surface 
GUCY2C which mediates endocytosis of the complex in 
a ligand- and GUCY2C cytoplasmic domain-independent, 
but clathrin-dependent, fashion, delivering ITs to 
lysosomes where they are cleaved, liberating cytotoxic 
dgRTA.
Figure 4: GUCY2C-targeted immunotoxin delivers dgRTA specifically to GUCY2C. (A) The design of cleavable ITsmpt 
conjugates of dgRTA and GUCY2C-specific mAb. (B) Immunoblot detecting ricin A chain under non-reducing (left) or reducing (right) 
conditions. Unconjugated GUCY2CmAb (mAb) and dgRTA served as controls for ITsmpt (reducible), ISOsmpt, and ITmbs (non-reducible) 
conjugates. (C, D) ELISA titration of GUCY2CmAb, ITmbs or ITsmpt on plates coated with BSA or GUCY2C1-430, detected with (C) anti-
mouse HRP or (D) anti-ricin/anti-rabbit HRP. Bars indicate means + SD of triplicate wells titrated from 0.01-10 µg/mL.
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Figure 5: GUCY2C-targeted ITsmpt cytotoxicity depends on GUCY2C, lysosomal cleavage, and clathrin. (A-D) CT26.
GUCY2C cells were treated with ITsmpt (A) or the isotype control toxin conjugate ISOsmpt (B) for 48 h prior to MTT assay to quantify 
cytotoxicity. (C) Parental CT26 cells served as a negative control. (D) CT26.GUCY2C cells also were treated with the non-cleavable 
ITmbs. (E, F) The clathrin-dependence of ITsmpt cytotoxicity was quantified in CT26.GUCY2C cells treated with (E) control or (F) 
clathrin-specific shRNAs. All treatments (A-F) were compared to mixed, but not conjugated, molar equivalents of antibody + dgRTA 
(MIX). Results are the mean ± SEM of at least 3 independent determinations.
Figure 6: GUCY2C-targeted ITsmpt reduces colorectal cancer metastases to lung and increases survival in mice. Mice 
were challenged IV with 5 x 105 CT26.GUCY2C cells and treated with 0.4 mg/kg ITsmpt or MIX every other day beginning two days 
after tumor challenge. (A, B) For some mice, lungs were collected on day 14, (A) stained, and (B) tumors enumerated. (C) Remaining 
mice (at least 9 per cohort) were followed for survival. **** p<0.0001, one-way ANOVA. (D) Tissue toxicities in mice treated with 0.4 
mg/kg ISOsmpt, 0.4 mg/kg ITsmpt, or vehicle control (3 mice per group). Histopathologic injury was scored as described in Materials and 
Methods.
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GUCY2C-Targeted IT Opposes Colorectal Cancer 
Metastases Without Injuring Normal Tissues
ITsmpt administered by tail vein to mice bearing 
CT26.GUCY2C lung metastases in a regimen of 40 mg/
kg every other day for 6 doses reduced tumor burden 
>80% (p<0.001) quantified after 12 days of therapy 
(Fig. 6A and B). In contrast, ITsmpt treatment of mice 
inoculated with parental CT26 cells was without effect 
on tumor metastases in lung (Sup. 7). Moreover, this 
regimen of ITsmpt increased survival 25% (p<0.001) 
in mice bearing CT26.GUCY2C lung metastases (Fig. 
6C). Importantly, this regimen of ITsmpt was without 
specific adverse effects in normal tissues, including sites 
in which GUCY2C is normally expressed (intestine, brain; 
Fig. 6D). Indeed, thorough histopathologic examination 
of brain, colon, epididymus, heart, kidney, liver, lung, 
salivary gland, small intestine, and spleen did not reveal 
any evidence of significant clinical toxicity specifically 
produced by the GUCY2C-targeted IT (Fig. 6D).
DISCUSSION
GUCY2C is uniquely suited as a therapeutic target 
for antibody-drug conjugates for metastatic disease. It 
is selectively expressed primarily by intestinal epithelia 
cells, from the duodenum to the rectum, where it is a key 
regulator of homeostatic processes organizing the crypt-
surface axis [38-41]. Also, GUCY2C is expressed by 
select hypothalamic neurons, where it mediates a novel 
gut-neural axis regulating appetite and satiety [19]. These 
anatomical compartments serve as barriers, with tight 
segregation from the systemic circulation, structurally 
and functionally insulating them from circulating 
GUCY2C-targeted cells and macromolecules [9-12, 
20]. Indeed, GUCY2C-targeted imaging agents in the 
circulation do not distribute to the gastrointestinal tract 
or central nervous system [10]. Moreover, GUCY2C-
targeted vaccines generate systemic T cell and antibody 
responses without affecting the gastrointestinal 
tract or central nervous system [23-25]. Beyond this 
compartmentalization, GUCY2C is over-expressed on the 
surface of primary and metastatic colorectal tumors [9, 22, 
42]. These characteristics, in which GUCY2C in normal 
tissues is compartmentalized and insulated outside the 
systemic compartment, but over-expressed on metastatic 
tumors residing within the systemic compartment, make 
it a highly specific functional tumor target to direct 
immunotoxins.
While anatomic compartmentalization coupled 
with general association with metastatic disease suggest 
unique utility as a therapeutic target, the cellular dynamics 
of GUCY2C, beyond its expression at the cell surface, 
has remained incompletely defined. The prevailing 
paradigm suggests that GUCY2C is primarily deployed 
in apical brush border membranes of intestinal epithelial 
cells, available to interact with its cognate paracrine 
ligands produced in the lumen of intestine [14, 29-32]. 
GUCY2C internalization has been quantified in vitro 
with radiolabeled ligand, although the intracellular fate 
of endocytosed complexes was unknown [43]. Similarly, 
imaging studies of tumors in mice using receptor-targeted 
ligands revealed accumulation of label inside tumor cells 
specifically mediated by GUCY2C although, again, the 
fate of internalized complexes remained undefined [10].
Here, development of monoclonal antibodies 
directed to the extracellular ligand-binding domain, but 
without effect on receptor activities (binding, catalytic 
activation), provided a unique opportunity to probe the 
fate of GUCY2C internalized from the cell surface. In 
striking contrast to the prevailing paradigm [14, 29-32], 
these analyses revealed that the majority of the GUCY2C 
associated with intestinal epithelial and colorectal cancer 
cells resided in the intracellular compartment, primarily 
in lysosomes. Live cell imaging directly visualized rapid 
internalization of GUCY2C from the cell surface into 
lysosomes. Like other guanylyl cyclases [44], endocytosis 
required clathrin, and disrupting its expression eliminated 
internalization of GUCY2C from the cell surface into 
lysosomes and the cytotoxic effects of GUCY2C-
targeted ITs. Importantly, GUCY2C internalization was 
independent of ligands, and trafficking to lysosomes 
required the extracellular ligand binding, but not the 
cytoplasmic catalytic, domain, like other guanylyl cyclases 
[45, 46].
These previously unknown mechanistic elements of 
GUCY2C endocytosis inform a strategy to employ this 
receptor as a therapeutic target in metastatic colorectal 
cancer. Rapid internalization of GUCY2C independent 
of ligand binding, receptor activation or the cytoplasmic 
catalytic domain supports therapeutic targeting with 
inert structural probes of the extracellular domain, like 
antibodies. Similarly, endocytosis from the cell surface 
into lysosomes suggests that targeted agents can leverage 
the unique characteristics of these organelles and 
incorporate cytotoxins and linkers that optimize liberation 
to maximize cytotoxicity. In that context, dgRTA cannot 
access the cytoplasmic compartment of cells in the 
absence of an internalization partner, like an antibody, 
enhancing the specificity for targeted killing [1, 2, 37]. 
Further, dgRTA accesses ribosomal cytotoxic targets by 
activation in, and translocation from, lysosomes [1, 2, 37]. 
Moreover, the SMPT linker produces a sterically-hindered 
disulfide bond which resists disruption in the circulation, 
but maximizes release of dgRTA in the acidic pH and 
reductive environment of lysosomes [1, 2, 36].
Employing this mechanism-directed strategy, ITs 
targeted by MS20 and delivering the cytotoxic dgRTA, 
linked together with SMPT, killed mouse colorectal cancer 
cells in vitro. ITsmpt cytotoxicity was highly specific for 
GUCY2C, and isogenic colorectal cancer cells devoid of 
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GUCY2C resisted cytotoxicity by this IT, while conjugates 
of non-specific immunoglobulin and dgRTA were inactive. 
Similarly, ITsmpt cytoxicity required internalization by 
antibody-GUCY2C complexes, and disrupting clathrin 
expression specifically eliminated IT efficacy, while 
mixtures of free MS20 and dgRTA were without effect. 
Moreover, IT cytotoxicity required activation in, and 
release from, lysosomes and MS20-dgRTA conjugates 
linked by the non-cleavable thioether MBS were 10- to 
100-fold less potent compared to ITsmpt. Beyond cells 
in vitro, this mechanism-based approach translated into 
effective therapy in mice with established colorectal 
cancer metastases in lung. Indeed, six doses of ITsmpt 
administered every other day reduced metastatic disease 
>80%, and improved survival 25%, compared to mice 
receiving a mixture of free MS20 and dgRTA. Further, the 
effects of the targeted IT were highly specific for GCC-
expressing tumors, and there were no obvious toxicities 
specifically associated with ITsmpt. In that context, tissues 
in which GUCY2C normally resides, including intestine 
and hypothalamus, were not affected by ITsmpt.
These studies reveal a novel biological mechanism 
mediating endocytosis of cell surface GUCY2C into 
lysosomes that is independent of receptor activity in 
normal intestinal epithelial and colorectal cancer cells. 
This mechanism can be leveraged to develop monoclonal 
antibody-directed ITs that specifically target GUCY2C-
expressing colorectal cancer metastases, maximizing the 
efficacy of tumor cell cytoxicity while minimizing off 
target adverse effects in normal tissues, including extra-
systemic compartments normally expressing GUCY2C. 
The emerging evolution in IT platforms, including 
humanizing monoclonal antibodies [47], novel cytotoxins 
like mayntansinoids [48], and next-generation scaffolds 
like pH-dependent boronate-linked linear-hyperbranched 
polymeric nanovehicles [49], underscores the importance 
of identifying therapeutic targets like GUCY2C that 
are tumor-specific, highly associated with disease, and 
mechanistically tractable to realize the full clinical 
potential of this therapeutic paradigm. The immediate 
translation of these approaches can best be appreciated 
by considering that beyond colorectal cancer, GUCY2C 
is ectopically expressed by a significant proportion of 
metastatic gastric, esophageal, and pancreatic tumors and 
GUCY2C-directed mAb ITs are in clinical development 
for their treatment [9, 50, 51].
MATERIALS AND METHODS
GUCY2C mAb Generation
The MS20 mAb was previously described [19]. 
MS7 and MS24 mAbs were similarly produced. All mAbs 
were purified with a protein G column (GE HiTrap Protein 
G HP, #17-0404-01).
Cyclic GMP Accumulation
CT26 mouse colorectal cancer cells engineered 
to express GUCY2C (CT26.GUCY2C) [23-25], were 
grown to confluence in DMEM + 10% fetal bovine 
serum in a 12-well dish washed with three times with 
PBS, and pretreated with 500uL DMEM containing 1 
mM 3-isobutyl-1-methylxanthine (IBMX) and 10 µg/mL 
antibody at 37°C for 30 min. Media was replaced with 500 
µL fresh DMEM/IBMX/antibody mix containing 1 µM 
ST and incubated for an additional 30 min at 37°C prior 
to collection. ST is the heat-stable enterotoxin produced 
by enteroxigenic bacteria that cause Travelers’ diarrhea. 
It was the first canonical ligand identified that binds to 
and activates GUCY2C in animals and humans [7]. 
Media concentrations of cGMP were determined by EIA, 
and normalized to protein concentration of cell lysates 
of respective wells determined by BCA assay. Non-
transfected CT26 cells were used as a negative control for 
ST treatment, an irrelevant mouse IgG was used as the 
control IgG.
Immunotoxin Generation
IT conjugates were generated as previously 
described [37]. Briefly, cleavable sulfosuccinimidyl 
6-[α-methyl-α-(2-pyridyldithio) toluamido] hexanoate 
(SMPT) or non-cleavable M-maleimid-obenzoyl-N-
hydoxysuccinimide ester (MBS) activated the antibody 
through an amine reaction for 1 h at room temperature. 
Simultaneously, deglycosylated Ricin Toxin A (dgRTA) 
domain (Sigma-Aldrich) was reduced with DTT to insure 
free sulfhydryl groups. Activated antibodies and reduced 
dgRTA were desalted on C18 columns, and then reacted 
for 72-96 h at varying stoichiometric ratios. Immunotoxins 
were then purified by size exclusion chromatography and 
confirmed by gel electrophoresis.
Immunotoxin ELISA
Binding competence of IT conjugates was confirmed 
using a GUCY2C extracellular domain (GUCY2C1-430)-
based ELISA [25]. ITs were incubated in GUCY2C1-430-
coated plates at varying concentrations. The mouse IgG 
component was detected with HRP-anti-mouse H + L 
(Jackson ImmunoResearch, #115-035-062). Ricin A chain 
was detected with rabbit-anti-Ricin antibody (Abcam, 
ab27169) followed by HRP-anti-rabbit H+L (Jackson 
ImmunoResearch, #111-035-003). Color was developed 
with Turbo-TMB substrate (Thermo Scientific, #34022) 
and quantified at λ480nm.
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Cell Imaging
Live imaging of sub-confluent cells plated on 
glass coverslips in 24 well plates was performed in 
media containing 25 mM HEPES. Prior to fixation, cells 
were incubated sequentially with primary antibody and 
fluorescent secondary antibody, and mounted on slides 
with DAPI Pro-long anti-fade mounting media and 
imaged by EVOS FL Auto (Life Technologies) or confocal 
microscopy (Zeiss 510M and Nikon C1 Plus, Thomas 
Jefferson University Bioimaging Shared Resource). Whole 
cell imaging was performed on CT26.GUCY2C cells, 
with parental CT26 cells as controls [23-25]. Methanol-
fixed cells were co-stained with antibodies for lysosomal 
associated membrane protein 1 (LAMP1, Abcam 
#24170), clathrin and GUCY2C mAb and reviewed by 
confocal microscopy. Endocytosis was examined using 
thermomechanical control, in which internalization was 
prevented at temperatures <4°C [33]. Cell surface imaging 
was performed on live cells by sequential exposure to 
primary antibody and fluorescent secondary antibody 
at 4°C followed by fixation. GUCY2C internalization 
was evaluated in live cells by confocal microscopy by 
sequential exposure to primary and secondary antibodies 
at 4°C, followed by warming to room temperature while 
time-lapse imaging. Live cells for time-lapse were 
counter-stained with live cell-permeable markers Hoechst 
for nuclei, and lysotracker red for lysosomes.
Targeted Inhibition of Gene Expression
GIPZ lentiviral mouse shRNA control or clathrin 
heavy chain constructs (Thermo Scientific) were 
transduced into sub-confluent cells by spinoculation for 
1.5 h at 2700 RPM with VSV-G pseudo-typed lentivirus, 
and clathrin protein expression quantified at 48 h. Mouse 
siRNA scrambled control or siRNAs to caveolin (Cav-
1; Ambion) were transfected into sub-confluent cells 
by using lipofectamine and Cav-1 protein expression 
quantified at 48 h.
Immunotoxin Toxicity
Cells, plated in 96 well plates at 80 percent 
confluence one day prior to treatment, were exposed 
to various concentrations of ITs for 48 h. Cells were 
then exposed to MTT ((3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) for 1 h and then 
solubilized overnight at 37°C. Absorbance at 590 nm was 
measured for each well and percent cell kill quantified by 
comparison to non-treated wells (0% cell kill) and wells 
incubated with a concentration of cycloheximide which 
produced 100% cytotoxicity, as follows: 
Metastatic Tumor Model
Mice were inoculated with 5 x 105 CT26.GUCY2C 
cells by tail vein 24 h prior to administration of 40 mg/
kg of IT, or matched concentrations of mixed free 
antibody and toxin, every other day for 6 doses. Mice 
were sacrificed on day 13, lungs injected with India ink 
and fixed for 48 h, and tumors quantified by blinded 
enumeration.
Tissue Histopathology
Hematoxylin and eosin-stained sections of the 
following organs were evaluated histologically by a board-
certified veterinary pathologist (LDBB): brain, colon, 
epididymis, heart, kidney, liver, lung, salivary gland, small 
intestine, and spleen. Sections were specifically evaluated 
for histopathologic evidence of cell degeneration, 
necrosis, apoptosis, inflammation, vasculitis, atrophy, 
and regeneration. The percentage of tissue parenchyma 
with evidence of histopathologic lesions were scored as 
follows: None (0% of the parenchyma affected): 0; Rare 
(<1% of the parenchyma affected): 1; Occasional (1-5% 
of the parenchyma affected): 2; Minimal (6-10% of the 
parenchyma affected): 3; Mild (11-30% of the parenchyma 
affected): 4; Moderate (31-60% of the parenchyma 
affected): 5; and Marked (61-100% of the parenchyma 
affected): 6. Tissues from at least 3 mice per group were 
evaluated to compile scores.
Statistical analysis
Statistical analyses were conducted using GraphPad 
Prism Software v5.
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IF, immunofluorescence staining; IT, immunotoxin; 
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peroxidase; LAMP1, lysosomal associated membrane 
protein 1; mAb, monoclonal antibody; RTA, Ricin Toxin 
A chain; ST, bacterial heat-stable enterotoxin.
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